Neil Woodford. Woodford Investment Management via YouTube
October 9, 2019 05:34 AM EDT
Financing

An­oth­er one of Neil Wood­ford's port­fo­lio com­pa­nies es­capes as UK biotech ex­ecs flee a col­lapse of faith

John Carroll

Editor & Founder

LON­DON — Ma­lin has joined the grow­ing queue of life sci­ences com­pa­nies that have man­aged to ex­tri­cate them­selves from a flail­ing Neil Wood­ford.

The biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times